Vidac Pharma Holding PLC: Reaches Last Patient Last Visit in Phase 2b Study of VDA-1102 in Actinic Keratosis

Completion of patient follow-up marks a key milestone ahead of data analysis

London (pta006/15.09.2026/08:40 UTC+2)

Vidac Pharma Holdings Plc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting cancer cell metabolism, today announced that the last patient's last visit in its Phase 2b clinical study evaluating VDA-1102 in highly proliferative Actinic Keratosis (AK) lesions took place on 9 September 2026.

The randomized, double-blind, placebo-controlled study evaluated topical VDA-1102 in patients with highly proliferative AK lesions at risk of progression to squamous cell carcinoma (SCC).

Patient recruitment was completed in June 2026.

With patient follow-up now completed, final data review is underway ahead of database lock and statistical analysis.

Dr. Max Herzberg, Chief Executive Officer of Vidac Pharma, commented: "Reaching the last patient's last visit represents an important milestone for Vidac Pharma and for the continued development of VDA-1102. No treatment-related serious adverse events have been reported to date. We would like to thank the patients, investigators and clinical teams who participated in the study. Final results, including the analysis of biopsy data, are expected in the coming weeks."

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, among others, those relating to the clinical development of VDA-1102, the analysis and interpretation of clinical study data, and future development and regulatory activities. Forward-looking statements are based on current expectations, assumptions, and information available to the Company at the time of publication and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, clinical trial outcomes, regulatory developments, financing availability, market conditions, and execution risks. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

About Vidac Pharma

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines for oncologic and onco-dermatologic diseases. The Company develops therapeutic candidates designed to modify the hyper-glycolytic tumor microenvironment by targeting the overexpression and mislocalization of the Hexokinase-2 (HK2) metabolic checkpoint in cancer cells, with the aim of renormalizing cellular metabolism and selectively inducing programmed cell death without affecting surrounding normal tissue. Vidac's lead drug candidate, VDA-1102, has previously demonstrated activity in clinical studies in Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL).

(end)

Emitter:	Vidac Pharma Holding PLC 20-22 Wenlock Road N1 7GU London United Kingdom
Contact Person:	Sandra Gamzon
Phone:	+972 544 999951
E-Mail:	investors@vidacpharma.com
Website:	www.vidacpharma.com
ISIN(s):	GB00BM9XQ619 (Share)
Stock Exchange(s):	Free Market in Dusseldorf (Primärmarkt), Hamburg, Stuttgart
Other Stock Exchanges:	XETRA